CTEV Stock - Claritev Corporation
Unlock GoAI Insights for CTEV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $930.62M | $961.52M | $1.08B | $1.12B | $937.76M |
| Gross Profit | $691.22M | $726.06M | $875.62M | $942.31M | $619.09M |
| Gross Margin | 74.3% | 75.5% | 81.1% | 84.3% | 66.0% |
| Operating Income | $-1,389,931,000 | $161.98M | $-362,732,000 | $386.12M | $-131,821,000 |
| Net Income | $-1,645,831,000 | $-91,697,000 | $-572,912,000 | $102.08M | $-520,564,000 |
| Net Margin | -176.9% | -9.5% | -53.1% | 9.1% | -55.5% |
| EPS | $-101.92 | $-5.69 | $-35.87 | $6.40 | $-44.23 |
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services. It provides payment and revenue integrity services, such as identifying and removing improper and unnecessary charges paid during the claim, as well as services to identify and help restore and preserve underpaid premium dollars. In addition, the company offers data and decision science services including a suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care; and business-to-business healthcare payments and other services. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 21st 2025 | Citigroup | Upgrade | Buy | $74 |
| May 29th 2025 | Piper Sandler | Upgrade | Overweight | $44 |
Earnings History & Surprises
CTEVEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $-3.96 | — | — | — |
Q4 2025 | Nov 7, 2025 | $-3.12 | $-4.07 | -30.4% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-2.69 | $0.32 | +111.9% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-2.20 | $-3.43 | -55.9% | ✗ MISS |
Q1 2025 | Feb 25, 2025 | $-9.81 | $-5.14 | +47.6% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $-2.37 | $-1.85 | +21.9% | ✓ BEAT |
Latest News
Claritev shares are trading lower after the company announced a common stock offering of 1,500,000 shares of its Class A common stock by certain affiliates of Hellman & Friedman.
📉 NegativeReported Earlier, Claritev Prices 1.5M Class A Shares At $51.50 In Offering By Selling Stockholders With 225K Share Option
➖ NeutralCORRECTION: Claritev Launches Public Offering Of 1.5M Shares By Hellman & Friedman Affiliates
➖ NeutralClaritev shares are trading lower after the company announced a common stock offering of 1,500,000 shares of its Class A common stock by certain affiliates of Hellman & Friedman.
📉 NegativeClaritev Launches Common Stock Offering On Behalf Of Certain Affiliates Of Hellman & Friedman; Terms Not Disclosed
➖ NeutralClaritev Expects FY25 Revenues To Rise 2.8%-3.2% YoY (Prior View: Flat To 2% YoY)
📈 PositiveClaritev Q3 EPS $(4.23) Misses $(3.38) Estimate, Sales $245.959M Beat $235.806M Estimate
➖ NeutralClaritev Corporation Announces Strategic Investment In Klaim To Launch A Co-Branded Payment Acceleration Service Within Claritev's Provider Network
📈 PositiveCitigroup Upgrades Claritev to Buy, Raises Price Target to $74
📈 PositiveClaritev shares are trading higher after the company announced that it renewed contracts with its largest 10 clients. Also, Citigroup upgraded the stock from Neutral to Buy and announced a $55 price target.
📈 PositiveCitigroup Upgrades Claritev to Buy, Announces $55 Price Target
📈 PositiveClaritev Says On October 15, Co Renewed Contracts With Its Largest 10 Clients, Representing 70% Of 2024 Revenue
📈 PositiveClaritev Secures Exclusive Rights To License, Integrate, And Resell iO Health's Optima AI platform In The Middle East And North Africa
📈 PositiveFrequently Asked Questions about CTEV
What is CTEV's current stock price?
What is the analyst price target for CTEV?
What sector is Claritev Corporation in?
What is CTEV's market cap?
Does CTEV pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CTEV for comparison